Azurity Pharmaceuticals, Inc

Wyzer Biosciences is a cutting-edge biotechnology company based in Cambridge, MA, specializing in innovative research and development within the life sciences industry. With a focus on advancing technologies and solutions in the field of biosciences, Wyzer Biosciences is dedicated to pushing the boundaries of scientific discovery and driving progress in healthcare and beyond. Generated from their business information

Fresenius Medical Care North America is part of Fresenius Medical Care, one of the world's largest, integrated providers of products and services for individuals with chronic kidney failure, a condition that affects more than 1.5 million individuals worldwide. Through its network of over 2,220 dialysis clinics in North America, Europe, Latin America and Asia-Pacific, Fresenius Medical Care provides dialysis treatment to 172,227 patients around the globe. Fresenius Medical Care is also the world's largest provider of dialysis products, such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care can trace its roots back to 1462, when The Fresenius family assumed ownership of Hirsch Pharmacy in Frankfurt, Germany. Approximately two-thirds of the company's research and development activities are based in Germany and one-third in North America. The company holds rights to more than 1,100 patents and patent applications relating to dialysis technology in major markets and own trademarks throughout the world.

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.